Provider Briefing: Cefepime Shortage in 2026

Cefepime injection — a cornerstone of empiric therapy for febrile neutropenia, complicated UTIs, hospital-acquired pneumonia, and serious gram-negative infections — remains in shortage as of March 2026. This article provides a concise, actionable briefing for providers and prescribers managing patients who require this fourth-generation cephalosporin.

For patient-facing information, see our patient shortage update.

Shortage Timeline

Cefepime has experienced recurring supply disruptions over the past decade, with the current cycle beginning in late 2022:

• 2010-2015: Initial shortage periods related to manufacturing quality issues across the sterile injectable market
• 2019: Brief shortage linked to increased demand and production delays
• 2022-2023: Significant shortage as multiple manufacturers experienced simultaneous production issues, compounded by post-pandemic supply chain constraints
• 2024-present: Ongoing shortage. B. Braun has cited manufacturing delays; other manufacturers (Baxter, Apotex, Hospira/Pfizer, Eugia/Aurobindo) have reported intermittent supply constraints across various NDCs

The ASHP continues to list Cefepime injection as an active shortage with no confirmed resolution date.

Prescribing Implications

The shortage creates several clinical considerations for prescribers:

Dose Optimization

When supply is limited, dose optimization strategies can help conserve available stock:

• Extended infusion protocols: Infusing Cefepime over 3-4 hours (rather than the standard 30 minutes) optimizes time-dependent pharmacokinetics and may allow for lower total daily doses in some patients while maintaining adequate drug exposure above the MIC.
• Renal dose adjustment: Ensure all patients with CrCl ≤60 mL/min receive appropriate dose reductions per labeling. This is critically important not only for conservation but for safety — the FDA's 2012 safety communication highlighted the risk of neurotoxicity (seizures, encephalopathy, myoclonus) in patients with renal impairment who did not receive appropriate dose adjustments.
• Therapeutic drug monitoring (TDM): Consider TDM for critically ill patients, those on renal replacement therapy, or patients with augmented renal clearance to ensure therapeutic levels while avoiding supratherapeutic concentrations.

Antibiotic Stewardship During Shortage

Drug shortages are an antibiotic stewardship challenge. Key principles include:

• Review culture and susceptibility data before defaulting to empiric Cefepime
• De-escalate to narrower-spectrum agents as soon as susceptibility results allow
• Consider whether an alternative empiric regimen (e.g., Piperacillin/Tazobactam) is equivalent for the clinical scenario
• Reserve remaining Cefepime stock for indications where it is most critical (e.g., febrile neutropenia, AmpC-producing Enterobacterales)

Current Availability Picture

Supply levels vary by formulation and manufacturer:

• 2 g vials: Most commonly backordered; this is the highest-volume formulation
• 1 g vials: Intermittently available; may require using two vials for a 2 g dose
• 500 mg vials: Generally more available but impractical for high-dose regimens
• Premixed bags (1 g/50 mL, 2 g/100 mL): Variable availability; some institutions report better access to premixed formulations

Supply fluctuates weekly. Medfinder for Providers offers real-time tracking of Cefepime availability across distributors and suppliers.

Alternative Agents

When Cefepime is unavailable, the following agents are appropriate alternatives depending on the clinical indication:

Ceftazidime

Third-generation cephalosporin with anti-Pseudomonal activity. Most direct substitute for Cefepime in many scenarios. Dose: 1-2 g IV every 8 hours. Note that Ceftazidime has less gram-positive coverage and greater susceptibility to some beta-lactamases compared to Cefepime.

Piperacillin/Tazobactam (Zosyn)

Extended-spectrum penicillin/beta-lactamase inhibitor. Provides excellent broad-spectrum coverage including anaerobes. Dose: 3.375-4.5 g IV every 6-8 hours. Consider for intra-abdominal infections and healthcare-associated pneumonia. Caution: also subject to periodic shortages.

Meropenem

Carbapenem with the broadest spectrum of the beta-lactams. Dose: 1-2 g IV every 8 hours. Reserve for critically ill patients, resistant organisms, or when other alternatives are also unavailable. Overuse contributes to carbapenem resistance.

Ceftazidime/Avibactam (Avycaz)

Effective against ESBL, AmpC, and some KPC-producing Enterobacterales. Dose: 2.5 g IV every 8 hours. Significantly more expensive but may be appropriate when resistant organisms are documented or suspected. See our detailed comparison in the alternatives guide.

Cost and Access Considerations

Cefepime pricing has been relatively stable as a generic injectable:

• Hospital acquisition cost: Approximately $5-15 per vial through group purchasing organizations, though shortage pricing may be higher
• Outpatient/home infusion cash price: $90-$400+ per course without insurance
• Insurance coverage: Generally covered under Medicare Part B (provider-administered) or commercial medical benefit; prior authorization is uncommon

For patients facing cost barriers, resources include NeedyMeds, RxAssist, hospital charity care programs, and state pharmaceutical assistance programs. No manufacturer savings programs exist since Cefepime is available only as a generic. Our provider's guide to helping patients save on Cefepime covers these options in detail.

Tools and Resources for Providers

• Medfinder for Providers: Real-time availability tracking for Cefepime and other shortage drugs
• ASHP Drug Shortage Resource Center: Shortage details, management strategies, and therapeutic substitution guidance
• FDA Drug Shortage Database: Official shortage listings and manufacturer status updates
• Institutional P&T committees: Many hospitals have developed Cefepime shortage management protocols including therapeutic interchange policies and allocation criteria

Looking Ahead

Several developments may improve the Cefepime supply outlook:

• Exblifep (Cefepime/Enmetazobactam): This FDA-approved combination product may offset some demand for standard Cefepime in appropriate indications
• New generic manufacturers: The FDA has signaled willingness to expedite ANDA approvals for shortage drugs
• 503B outsourcing facilities: Some 503B pharmacies are compounding Cefepime under FDA oversight, adding supplemental supply

However, the structural challenges of the sterile injectable market — high manufacturing costs, low profit margins for generic drugs, and a small number of producers — mean that shortages are likely to recur even after the current cycle resolves.

Final Thoughts

The Cefepime shortage demands proactive management from prescribers: optimizing doses, leveraging stewardship principles, knowing your alternatives, and using tools like Medfinder for Providers to track supply in real time. Transparent communication with patients about the shortage and any treatment changes is also essential.

We will continue to update this briefing as the situation evolves. For guidance on helping individual patients find Cefepime, see our provider's guide to helping patients find Cefepime in stock.